Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 2/20 | 0.32 |
| ▸ | ACACB | O00763 | 4/20 | 0.32 |
| ▸ | ACACA | Q13085 | 4/20 | 0.32 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20038151 | 0.80 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3GRM5ACACB | |
| SCHEMBL18291645 | 0.80 | SLC6A2 (0.36) | SLC6A2SLC6A4SLC6A3GRM5ACACB | |
| SCHEMBL20249243 | 0.78 | CDK4 (0.40) | CDK4 | |
| SCHEMBL20249397 | 0.78 | OPRL1 (0.40) | SLC6A2SLC6A4SLC6A3OPRL1SIGMAR1 | |
| SCHEMBL30329301 | 0.75 | OPRL1 (0.45) | OPRL1SIGMAR1GRM5ACACBACACA | |
| Hydrochloric Acid SCHEMBL30329056 | 0.74 | OPRL1 (0.44) | SLC6A2SLC6A4SLC6A3OPRL1SIGMAR1 | |
| SCHEMBL21423162 | 0.72 | SLC6A2 (0.42) | SLC6A2SLC6A4SLC6A3TMEM97SIGMAR1 | |
| SCHEMBL20249254 | 0.71 | HTR6 (0.40) | SLC6A2 | |
| SCHEMBL20249248 | 0.71 | TSHR (0.41) | CDK4 | |
| SCHEMBL20249282 | 0.71 | RAB9A (0.36) | OPRL1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | SLC6A2 2659/4885SLC6A4 1825/4885SLC6A3 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.